- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01896115
CUSTOM-DBS: Current Steering to Optimize Deep Brain Stimulation (CUSTOM-DBS)
Current Steering to Optimize Deep Brain Stimulation
연구 개요
상세 설명
The study is a prospective, multi-center, double-blind, randomized controlled trial.
This study will compare various program settings for the bilateral stimulation of the STN using the BSC implantable Vercise™ DBS System for the treatment of levodopa-responsive, moderate to severe idiopathic PD.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Berlin, 독일
- University Berlin, Charite Virchow
-
Düsseldorf, 독일
- Universitaetsklinikum Dusseldorf
-
Kiel, 독일
- Universitätsklinikum Campus Kiel
-
Köln, 독일
- Uniklinik Koln
-
Wurzburg, 독일
- Universitaetsklinikum Wuerzburg
-
-
-
-
California
-
Valencia, California, 미국, 91355
- Boston Scientific Clinical Research Information Toll Free Number
-
-
-
-
-
Bristol, 영국
- Southmead Hospital Bristol
-
London, 영국
- Charing Cross Hospital
-
-
-
-
-
Innsbruck, 오스트리아
- A.o. LKH Univ.-Kliniken Innsbruck
-
-
-
-
-
Udine, 이탈리아
- Osp. S. Maria Della Misericordia
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Implanted bilaterally in STN with a Vercise DBS system for Parkinson's disease for at least three months with programming optimized according to standard of care.
- UPDRS subset III score of ≥30 in the in the pre-operative meds off state.
- DBS must improve PD symptoms by ≥30% in the meds off state, as measured by UPDRS subset III score.
- Medical and mental fitness to comply with programming visit and study related procedures.
- Able to understand the study requirements and the treatment procedures and provides written informed consent before any study-specific tests or procedures are performed.
- Off symptom rigidity score of ≥2 in the evaluated arm as determined by the UPDRS-III.
Exclusion Criteria:
- Have any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints, including any terminal illness with survival <12 months.
- Resting and/or action tremor score of ≥3 on the evaluated side as determined by the UPDRS-III in pre-operative meds off condition.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Short PW
Patients with a Vercise DBS system programmed to 30 microseconds pulse width
|
Deep brain stimulation set at short pulse width and monopolar stimulation using current steering
|
실험적: Conventional PW
Patients with a Vercise DBS system programmed to 60 microseconds pulse width
|
Deep brain stimulation set at short pulse width and monopolar stimulation using current steering
|
실험적: Ventral current steering
Patients with a Vercise DBS system programmed to steer current ventrally
|
Deep brain stimulation set at short pulse width and monopolar stimulation using current steering
|
실험적: Dorsal current steering
Patients with a Vercise DBS system programmed to steer current dorsally.
|
Deep brain stimulation set at short pulse width and monopolar stimulation using current steering
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Therapeutic Window
기간: Day 1 programming visit
|
The therapeutic window refers to the range of stimulus amplitudes that provide a therapeutic effect without side effects.
In other words, it is the amplitude difference between the first stimulation-induced side effect threshold (e.g., eye deviation, muscle contraction, and speech) and full rigidity control threshold at 60 µs and 30 µs pulse width DBS settings.
|
Day 1 programming visit
|
Unified Parkinson's Disease Rating Scale III
기간: Day 1 programming visit
|
The Unified Parkinson's Disease Rating Scale (UPDRS) has four sections (I-IV) that ask patients to rate aspects of their mental state including mood (I), aspects of daily activities (II), aspects of motor function (III), and complications of treatment (IV). Here, we ask subjects to rate their motor function (UPDRS III) following interventions with 30 µs and 60 µs pulse width DBS settings. The UPDRS III scale has 14 categories including speech, facial expression, tremor at rest, action tremor, rigidity, finger tapping ability, ability to open and close hands, ability to rapidly alternate hand movements, leg agility, ability to rise from a chair, posture, gait, response to postural displacement (e.g., push), and bradykinesia. Patients rate each of these categories from 0 to 4, with 0 being normal function and 4 being the worst. Categories assessing appendages are rated for both left and right sides, allowing a maximum score (worst outcome) of 108. |
Day 1 programming visit
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Side Effect Thresholds - Single Contact vs. Steering
기간: Day 1 programming visit
|
This endpoint determined how much current (mA) could be applied before side effects appeared when using 60 microsecond pulse widths.
Values were obtained for when current was delivered through a single contact or divided between two contacts (steering).
|
Day 1 programming visit
|
Resting Tremor Severity - Single Contact vs. Steering
기간: Day 1 programming visit
|
Resting tremor was measured by a motion sensor system (Kinesia System) while either using a single contact or steering current between two contacts.
Stimulation was at amplitudes defined as the therapeutic threshold for rigidity.
The Kinesia System was worn by patients to measure motion parameters including linear acceleration and angular velocity during different tasks, then provided an output score on a scale of 0 (no symptoms) to 4 (severe symptoms).
|
Day 1 programming visit
|
Finger Tapping Amplitude - Single Contact vs. Steering
기간: Day 1 programming visit
|
Severity of finger-tapping bradykinesia was measured by a motion sensor system (Kinesia System) when either using a single contact or steering current between two contacts.
Stimulation was at amplitudes defined as the therapeutic threshold for rigidity.
The Kinesia System was worn by patients to measure motion parameters including linear acceleration and angular velocity during different tasks, then provided an output score on a scale of 0 (no symptoms) to 4 (severe symptoms).
|
Day 1 programming visit
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Dorsal-Ventral Current Steering Therapeutic Window
기간: Day 1 programming visit
|
The therapeutic window refers to the range of stimulus amplitudes that provide a therapeutic effect without side effects.
In other words, this measure reports the stimulus amplitude difference between the full rigidity control threshold and the first stimulation induced side effect threshold at current steering settings (current divided 50% between adjacent electrodes).
|
Day 1 programming visit
|
Resting Tremor Severity - Pulse Width and Dorsal-Ventral Steering
기간: Day 1 programming Visit
|
Resting tremor was measured by a motion sensor system (Kinesia System) at 60 µs, 30 µs, and current steering settings, at amplitudes defined as the therapeutic threshold for rigidity.
The Kinesia System was worn by patients to measure motion parameters including linear acceleration and angular velocity during different tasks, then provided an output score on a scale of 0 (no symptoms) to 4 (severe symptoms).
|
Day 1 programming Visit
|
Finger Tapping Amplitude - Pulse Width and Dorsal-Ventral Steering
기간: Day 1 programming visit
|
Severity of finger-tapping bradykinesia was measured by a motion sensor system (Kinesia System) at 60 µs, 30 µs, and dorsal and ventral current steering settings.
Stimulation was at amplitudes defined as the therapeutic threshold for rigidity.
The Kinesia System was worn by patients to measure motion parameters including linear acceleration and angular velocity during different tasks, then provided an output score on a scale of 0 (no symptoms) to 4 (severe symptoms).
|
Day 1 programming visit
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Vercise DBS settings에 대한 임상 시험
-
Boston Scientific Corporation모병파킨슨 병미국, 대한민국, 이탈리아, 폴란드, 스페인, 프랑스, 독일, 이스라엘, 영국, 캐나다, 아르헨티나, 오스트리아, 벨기에, 헝가리
-
Boston Scientific Corporation모병디스토니아독일, 영국, 이탈리아, 벨기에, 헝가리, 이스라엘, 네덜란드, 폴란드, 러시아 연방, 스페인, 대한민국
-
University Hospital FreiburgBoston Scientific Corporation모병
-
Jonathan JagidBoston Scientific Corporation모병
-
University of Alabama at BirminghamNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes of...모집하지 않고 적극적으로
-
University of Alabama at BirminghamMichael J. Fox Foundation for Parkinson's Research완전한
-
Allegheny Singer Research Institute (also known...Boston Scientific Corporation모병